{"id":"timolol-0-5-bid","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"1-5%","effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Timolol works by blocking the action of epinephrine and norepinephrine on beta-adrenergic receptors in the eye, leading to a decrease in intraocular pressure. This is achieved through a reduction in aqueous humor production and an increase in uveoscleral outflow. The net effect is a decrease in intraocular pressure, which is beneficial for patients with glaucoma.","oneSentence":"Timolol is a non-selective beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:45.720Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07495852","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2026-02-17","conditions":"Glaucoma","enrollment":510},{"nctId":"NCT07474883","phase":"EARLY_PHASE1","title":"Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Pham Ngoc Thach University of Medicine","startDate":"2026-03-09","conditions":"Post Inflammtory Erythema, Acne Vulgaris, Erythema","enrollment":60},{"nctId":"NCT05479123","phase":"PHASE4","title":"Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-06-23","conditions":"Infantile Hemangioma","enrollment":52},{"nctId":"NCT04412096","phase":"PHASE4","title":"Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2020-11-23","conditions":"Glaucoma, OHT - Ocular Hypertension","enrollment":59},{"nctId":"NCT07075718","phase":"PHASE2, PHASE3","title":"Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2025-06-12","conditions":"Glaucoma","enrollment":610},{"nctId":"NCT06030193","phase":"PHASE2","title":"Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qlaris Bio, Inc.","startDate":"2025-08-13","conditions":"Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye","enrollment":36},{"nctId":"NCT07168902","phase":"PHASE2","title":"Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-10-24","conditions":"Glaucoma","enrollment":228},{"nctId":"NCT07218796","phase":"PHASE3","title":"Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)","status":"RECRUITING","sponsor":"SpyGlass Pharma, Inc.","startDate":"2025-10-28","conditions":"Cataract, Glaucoma, Ocular Hypertension","enrollment":400},{"nctId":"NCT07218783","phase":"PHASE3","title":"Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)","status":"RECRUITING","sponsor":"SpyGlass Pharma, Inc.","startDate":"2025-10-15","conditions":"Cataract, Glaucoma, Ocular Hypertension","enrollment":400},{"nctId":"NCT05913232","phase":"PHASE2","title":"Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"D. Western Therapeutics Institute, Inc.","startDate":"2023-08-28","conditions":"Glaucoma Open-Angle Primary, Ocular Hypertension","enrollment":201},{"nctId":"NCT06120842","phase":"PHASE1, PHASE2","title":"Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution","status":"ACTIVE_NOT_RECRUITING","sponsor":"SpyGlass Pharma, Inc.","startDate":"2023-10-13","conditions":"Cataract, Glaucoma, Ocular Hypertension","enrollment":201},{"nctId":"NCT02484716","phase":"PHASE2","title":"Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-06","conditions":"Telangiectasia, Hereditary Hemorrhagic, Osler Rendu Disease","enrollment":58},{"nctId":"NCT04149899","phase":"PHASE1, PHASE2","title":"Safety and IOP-Lowering Effects of WB007","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2019-11-14","conditions":"Glaucoma, Primary Open Angle, Ocular Hypertension","enrollment":77},{"nctId":"NCT04857827","phase":"PHASE2","title":"A Study to Evaluate Safety and Tolerability of QLS-101 in NTG","status":"COMPLETED","sponsor":"Qlaris Bio, Inc.","startDate":"2021-09-15","conditions":"Normal Tension Glaucoma (NTG)","enrollment":30},{"nctId":"NCT06761313","phase":"PHASE4","title":"Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2021-03-01","conditions":"Glaucoma, Quality of Life (QOL)","enrollment":40},{"nctId":"NCT06677853","phase":"PHASE2, PHASE3","title":"Timolol Maleate Gel for the Treatment of Infantile Hemangioma","status":"COMPLETED","sponsor":"Auson Pharmaceuticals Inc.","startDate":"2020-10-28","conditions":"Infantile Hemangioma","enrollment":168},{"nctId":"NCT06643416","phase":"PHASE3","title":"Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia","status":"RECRUITING","sponsor":"Queen Mary Hospital, Hong Kong","startDate":"2024-10-09","conditions":"Paronychia, EGFR-TKI, ALK-TKI","enrollment":40},{"nctId":"NCT02053298","phase":"PHASE4","title":"Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-01","conditions":"Open Angle Glaucoma","enrollment":30},{"nctId":"NCT05503901","phase":"PHASE3","title":"A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2022-08-08","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":131},{"nctId":"NCT04910100","phase":"PHASE2","title":"Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension","status":"COMPLETED","sponsor":"Betaliq, Inc.","startDate":"2021-04-15","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":226},{"nctId":"NCT06140186","phase":"PHASE3","title":"Efficacy and Safety of Timolol for TKI Induced Paronychia","status":"UNKNOWN","sponsor":"Queen Mary Hospital, Hong Kong","startDate":"2023-04-01","conditions":"Paronychia","enrollment":40},{"nctId":"NCT06152861","phase":"PHASE2","title":"Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension","status":"UNKNOWN","sponsor":"Glaukos Corporation","startDate":"2023-11-15","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":250},{"nctId":"NCT01873131","phase":"NA","title":"A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2011-02","conditions":"Hemangioma","enrollment":126},{"nctId":"NCT02754596","phase":"PHASE2","title":"Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2016-03-29","conditions":"Glaucoma Open-angle","enrollment":154},{"nctId":"NCT01752049","phase":"PHASE1, PHASE2","title":"Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2013-05","conditions":"Hereditary Hemorrhagic Telangiectasia","enrollment":5},{"nctId":"NCT03691649","phase":"PHASE3","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-14","conditions":"Glaucoma and Ocular Hypertension","enrollment":426},{"nctId":"NCT03931317","phase":"NA","title":"Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2018-12-03","conditions":"OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension","enrollment":70},{"nctId":"NCT03691662","phase":"PHASE3","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-27","conditions":"Glaucoma and Ocular Hypertension","enrollment":417},{"nctId":"NCT04742283","phase":"PHASE2","title":"Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2020-12-17","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":323},{"nctId":"NCT05165082","phase":"NA","title":"The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitors-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study","status":"COMPLETED","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2021-12-21","conditions":"Paronychia, Epidermal Growth Factor Receptor Inhibitor","enrollment":8},{"nctId":"NCT04296916","phase":"NA","title":"Effect of Lowering IOP in Glaucoma Suspects With HM","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-17","conditions":"Glaucoma, Suspect, High Myopia","enrollment":264},{"nctId":"NCT04064918","phase":"NA","title":"Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity","status":"WITHDRAWN","sponsor":"University of California, San Diego","startDate":"2021-12","conditions":"OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension","enrollment":""},{"nctId":"NCT04139018","phase":"PHASE2","title":"Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-10-20","conditions":"Hereditary Hemorrhagic Telangiectasia","enrollment":27},{"nctId":"NCT03648229","phase":"PHASE4","title":"African Glaucoma Laser Trial","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2019-09-01","conditions":"Open-angle Glaucoma","enrollment":""},{"nctId":"NCT02955849","phase":"EARLY_PHASE1","title":"A Trial of China Laser and Surgery Study Glaucoma in Rural China","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-09","conditions":"Glaucoma","enrollment":200},{"nctId":"NCT00716859","phase":"PHASE3","title":"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-07","conditions":"Glaucoma","enrollment":139},{"nctId":"NCT02250612","phase":"PHASE2","title":"SYL040012, Treatment for Open Angle Glaucoma","status":"COMPLETED","sponsor":"Sylentis, S.A.","startDate":"2014-10","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":184},{"nctId":"NCT02358369","phase":"PHASE2","title":"Dose-Ranging Study of the Bimatoprost Ocular Insert","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2015-01-19","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":156},{"nctId":"NCT01257698","phase":"NA","title":"Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy","status":"COMPLETED","sponsor":"Mid Atlantic Retina","startDate":"2010-02","conditions":"Macular Hole, Retinal Detachment","enrollment":21},{"nctId":"NCT01062971","phase":"PHASE2","title":"Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2006-02","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":124},{"nctId":"NCT02730871","phase":"PHASE4","title":"Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2016-06-24","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT01533376","phase":"PHASE1","title":"Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol","status":"TERMINATED","sponsor":"Wills Eye","startDate":"2012-02","conditions":"Sturge Weber Syndrome, Port-wine Mark","enrollment":3},{"nctId":"NCT02742649","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2016-04-30","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":55},{"nctId":"NCT01749930","phase":"PHASE3","title":"Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":420},{"nctId":"NCT02731287","phase":"PHASE2","title":"Topical Timolol for Infantile Hemangioma in Early Proliferative Phase","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2014-03","conditions":"Hemangioma","enrollment":70},{"nctId":"NCT01749904","phase":"PHASE3","title":"Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01-31","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":420},{"nctId":"NCT01254604","phase":"PHASE3","title":"Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":190},{"nctId":"NCT01707381","phase":"PHASE2","title":"BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2012-11","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":25},{"nctId":"NCT01915940","phase":"PHASE2","title":"Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2013-10-23","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":169},{"nctId":"NCT02207491","phase":"PHASE3","title":"Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2014-07","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":411},{"nctId":"NCT02558374","phase":"PHASE3","title":"Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2015-09","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":708},{"nctId":"NCT02246764","phase":"PHASE3","title":"Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2014-09","conditions":"Ocular Hypertension, Glaucoma","enrollment":93},{"nctId":"NCT02207621","phase":"PHASE3","title":"Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2014-07","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":756},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT01147601","phase":"EARLY_PHASE1","title":"Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas","status":"TERMINATED","sponsor":"Oregon Health and Science University","startDate":"2010-03","conditions":"Hemangioma, Infant","enrollment":6},{"nctId":"NCT01026831","phase":"PHASE3","title":"Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-01-06","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":643},{"nctId":"NCT00545064","phase":"PHASE4","title":"Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-05-23","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":176},{"nctId":"NCT00824824","phase":"NA","title":"Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2009-01","conditions":"Glaucoma","enrollment":21},{"nctId":"NCT00546286","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05-31","conditions":"Glaucoma, Ocular Hypertension","enrollment":170},{"nctId":"NCT02145884","phase":"PHASE2","title":"Topical Timolol Gel for the Treatment of Infantile Hemangiomas","status":"COMPLETED","sponsor":"Rady Children's Hospital, San Diego","startDate":"2014-05","conditions":"Hemangioma","enrollment":26},{"nctId":"NCT01217606","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":185},{"nctId":"NCT02312544","phase":"PHASE2","title":"Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2014-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":72},{"nctId":"NCT01845038","phase":"PHASE1","title":"Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2013-04","conditions":"Glaucoma","enrollment":41},{"nctId":"NCT02325518","phase":"PHASE4","title":"Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution","status":"COMPLETED","sponsor":"Alcon, a Novartis Company","startDate":"2014-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":218},{"nctId":"NCT02565173","phase":"PHASE3","title":"Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Inotek Pharmaceuticals Corporation","startDate":"2015-09","conditions":"Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)","enrollment":303},{"nctId":"NCT01434849","phase":"PHASE1","title":"Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)","status":"TERMINATED","sponsor":"Alice K. Gong","startDate":"2012-07","conditions":"Infantile Hemangioma, Very Low Birth Weight Infants","enrollment":26},{"nctId":"NCT02003391","phase":"PHASE4","title":"Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":157},{"nctId":"NCT02165631","phase":"","title":"The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-08","conditions":"Open Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Syndrome","enrollment":60},{"nctId":"NCT01518244","phase":"PHASE4","title":"Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-12","conditions":"Glaucoma","enrollment":50},{"nctId":"NCT01111890","phase":"PHASE4","title":"Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":70},{"nctId":"NCT01652664","phase":"PHASE3","title":"Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-09","conditions":"Pediatric Glaucoma, Elevated IOP in Pediatric Patients, Ocular Hypertension in Pediatric Patients","enrollment":184},{"nctId":"NCT01342094","phase":"PHASE3","title":"DE-111 Against Timolol Ophthalmic Solution 0.5%","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2011-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":166},{"nctId":"NCT01607671","phase":"PHASE1","title":"Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%","status":"WITHDRAWN","sponsor":"Fraser Health","startDate":"2012-06","conditions":"Optic Neuropathy, Ischemic, Anterior Ischemic Optic Neuropathy, Ischemic Optic Neuropathy","enrollment":""},{"nctId":"NCT02061735","phase":"","title":"Ontogeny of Infantile Hemangiomas With Skin Imaging Modalities","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2011-10","conditions":"Infantile Hemangiomas","enrollment":118},{"nctId":"NCT01978600","phase":"PHASE4","title":"Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":89},{"nctId":"NCT00823043","phase":"","title":"A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs","status":"COMPLETED","sponsor":"Vistakon Pharmaceuticals","startDate":"2009-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":103},{"nctId":"NCT00275756","phase":"NA","title":"Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans","status":"WITHDRAWN","sponsor":"Medical University of Vienna","startDate":"2008-09","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT01241240","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-03","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":192},{"nctId":"NCT01415401","phase":"PHASE4","title":"Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Glaucoma, Ocular Hypertension, Open-angle Glaucoma","enrollment":57},{"nctId":"NCT01263444","phase":"PHASE4","title":"Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT01357616","phase":"PHASE3","title":"Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-11","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":328},{"nctId":"NCT01340014","phase":"PHASE4","title":"Patient Preference Comparison of AZARGA Versus COSOPT","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":112},{"nctId":"NCT01408056","phase":"PHASE2","title":"Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)","status":"WITHDRAWN","sponsor":"Children's Hospital of Philadelphia","startDate":"2011-02","conditions":"Infantile Hemangiomas","enrollment":""},{"nctId":"NCT01514734","phase":"PHASE4","title":"Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2012-03","conditions":"Glaucoma","enrollment":9},{"nctId":"NCT01216943","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":126},{"nctId":"NCT01284166","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2013-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT01484951","phase":"PHASE4","title":"AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-05","conditions":"Glaucoma","enrollment":74},{"nctId":"NCT01520116","phase":"PHASE1, PHASE2","title":"Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension","status":"UNKNOWN","sponsor":"Altheos, Inc.","startDate":"2012-01","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":180},{"nctId":"NCT01250457","phase":"PHASE4","title":"Topical Timolol for the Treatment of Benign Vascular Periocular Lesions","status":"WITHDRAWN","sponsor":"Loyola University","startDate":"2010-06","conditions":"Benign Vascular Periocular Lesions","enrollment":""},{"nctId":"NCT00508469","phase":"PHASE4","title":"Adherence Assessment With Travalert Dosing Aid","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-10","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":102},{"nctId":"NCT01434888","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops","status":"COMPLETED","sponsor":"Santen Oy","startDate":"2011-09","conditions":"Healthy Volunteers","enrollment":15},{"nctId":"NCT01506635","phase":"NA","title":"Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After LASIK: a Randomized Clinical Trial","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2010-03","conditions":"Myopic Regression","enrollment":45},{"nctId":"NCT01446497","phase":"PHASE4","title":"Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2010-10","conditions":"Normal Tension Glaucoma","enrollment":22},{"nctId":"NCT00763061","phase":"PHASE4","title":"Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-05","conditions":"Glaucoma","enrollment":111},{"nctId":"NCT00822055","phase":"PHASE4","title":"Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":140},{"nctId":"NCT00822081","phase":"PHASE4","title":"Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2005-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":140},{"nctId":"NCT00804115","phase":"NA","title":"The International Collaborative Exfoliation Syndrome Treatment Study","status":"UNKNOWN","sponsor":"The New York Eye & Ear Infirmary","startDate":"2000-08","conditions":"Exfoliation Syndrome, Glaucoma, Ocular Hypertension","enrollment":277},{"nctId":"NCT00698945","phase":"PHASE4","title":"Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-06","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":40},{"nctId":"NCT00800423","phase":"PHASE3","title":"Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2009-01","conditions":"Corneal Edema, Visual Acuity","enrollment":150},{"nctId":"NCT00651612","phase":"PHASE3","title":"Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":604}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Timoptic"],"phase":"phase_3","status":"active","brandName":"timolol 0.5% BID","genericName":"timolol 0.5% BID","companyName":"Inotek Pharmaceuticals Corporation","companyId":"inotek-pharmaceuticals-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Timolol 0.5% is a beta-1 adrenergic receptor antagonist used to treat conditions such as glaucoma and ocular hypertension. It is administered twice daily as a topical eyedrop.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}